Attenuation of niacin-induced prostaglandin D 2 generation by omega-3 fatty acids in THP-1 macrophages and Langerhans dendritic cells

Journal of Inflammation Research

Volumn 5, Issue 1, 2012, Pages 37-50

  VanHorn, Justin ^a   Altenburg, Jeffrey D ^a   Harvey, Kevin A ^a   Xu, Zhidong ^a   Kovacs, Richard J ^b   Siddiqui, Rafat A ^a,c  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arachidonic acid; Cardiovascular; Docosahexaenoic acid; Flushing; GPR109A; Phospholipids; Prostaglandin E 2

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHOSPHOLIPASE A2; PROSTAGLANDIN D2; PROSTAGLANDIN E2;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LANGERHANS CELL; LIPID COMPOSITION; MACROPHAGE; PROTEIN EXPRESSION;

EID: 84859056332     PISSN: None     EISSN: 11787031     Source Type: Journal    
DOI: 10.2147/JIR.S29044     Document Type: Article

References (73)

1. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol. 2004;15(6):659-665.
2. th anniversary review. J Intern Med. 2005;258(2):94-114.
3. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231(4): 360-381.
4. van Greevenbroek MM, Voorhout WF, Erkelens DW, van Meer G, de Bruin TW. Palmitic acid and linoleic acid metabolism in Caco-2 cells: different triglyceride synthesis and lipoprotein secretion. J Lipid Res. 1995;36(1):13-24.
5. Wahlberg G, Walldius G, Olsson AG, Kirstein P. Effects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2 and HDL3 in hyperlipoproteinaemia. J Intern Med. 1990;228(2):151-157.
6. Ganji SH, Zhang L-H, Kamanna VS, Kashyap ML. Effect of niacin on lipoproteins and atherosclerosis. Future Lipidol. 2006;1(5):549.
7. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998;82(12A):74U-81U; discussion 85U-86U.
8. Backes JM, Gibson CA. Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein. Ann Pharmacother. 2005;39(3): 523-526.
9. Parhofer KG. Review of extended-release niacin/laropiprant f ixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag. 2009;5: 901-908.
10. Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin. 2006;22(2): 417-425.
11. Ballantyne CM, Davidson MH, McKenney JM, Keller LH, Bajorunas DR, Karas RH. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol. 2008;2(2):79-90.
12. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008;101(10):1428-1436.
13. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341(7): 498-511.
14. Shepherd J, Packard CJ, Patsch JR, Gotto AM Jr, Taunton OD. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 1979;63(5):858-867.
15. National Heart, Lung, and Blood Institute. HDL-atherosclerosis treatment study (HATS). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 1999 [updated June 23, 2005]. Available from: http://clinicaltrials.gov/ct2/show/NCT00000553?term=NCT00000553&rank=1. NLM identifier: NCT00000553. Accessed February 10, 2012.
16. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583-1592.
17. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267.
18. National Heart, Lung, and Blood Institute. Niacin plus statin to prevent vascular events. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2005 [updated June 3, 2011]. Available from: http://clinicaltrials.gov/ct2/show?term=NCT00120289&rank=1. NLM identifier: NCT00120289. Accessed February 12, 2012
19. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med. 1994;121(4):252-258.
20. Stern RH, Spence JD, Freeman DJ, Parbtani A. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther. 1991;50(1):66-70.
21. Nozaki S, Kihara S, Kubo M, Kameda K, Matsuzawa Y, Tarui S. Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing. Int J Clin Pharmacol Ther Toxicol. 1987;25(12):643-647.
22. Morrow JD, Parsons WG III, Roberts LJ II. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 1989;38(2): 263-274.
23. Eklund B, Kaijser L, Nowak J, Wennmalm A. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins. 1979;17(6):821-830.
24. Maciejewski-Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol. 2006;126(12): 2637-2646.
25. Benyo Z, Gille A, Bennett CL, Clausen BE, Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol. 2006;70(6):1844-1849.
26. Lorenzen A, Stannek C, Burmeister A, Kalvinsh I, Schwabe U. G protein-coupled receptor for nicotinic acid in mouse macrophages. Biochem Pharmacol. 2002;64(4):645-648.
27. Soga T, Kamohara M, Takasaki J, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun. 2003;303(1): 364-369.
28. Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003;278(11): 9869-9874.
29. Benyo Z, Gille A, Kero J, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2005;115(12): 3634-3640.
30. Cheng K, Wu T-J, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006;103(17):6682-6687.
31. Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med. 1997;336(15):1046-1053.
32. Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA. 1998;279(1):23-28.
33. Bang HO, Dyerberg J, Hjoorne N. The composition of food consumed by Greenland Eskimos. Acta Med Scand. 1976;200(1-2): 69-73.
34. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354(9177):447-455.
35. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alphalinolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343(8911):1454-1459.
36. Leaf A, Albert CM, Josephson M, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation. 2005;112(18):2762-2768.
37. Harris WS. n-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids. 1996;31(3):243-252.
38. Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000;71(5):1085-1094.
39. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4(5-6):385-391.
40. Abe Y, El-Masri B, Kimball KT, et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol. 1998;18(5):723-731.
41. McKenney JM, Sica D. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am J Health Syst Pharm. 2007;64(6): 595-605.
42. Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Ann Rev Biochem. 2001;70:281-312.
43. Liberty IF, Raichel L, Hazan-Eitan Z, et al. Cytosolic phospholipase A2 is responsible for prostaglandin E2 and leukotriene B4 formation in phagocyte-like PLB-985 cells: studies of differentiated cPLA2-deficient PLB-985 cells. J Leukoc Biol. 2004;76(1):176-184.
44. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res. 2000;41(2): 163-181.
45. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271(52): 33157-33160.
46. Stillwell W, Shaikh SR, Zerouga M, Siddiqui R, Wassall SR. Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod Nutr Dev. 2005;45(5):559-579.
47. Horejsi V, Drbal K, Cebecauer M, et al. GPI-microdomains: a role in signaling via immunoreceptors. Immunol Today. 1999;20(8): 356-361.
48. Siddiqui RA, Harvey KA, Zaloga GP, Stillwell W. Modulation of lipid rafts by omega-3 fatty acids in inflammation and cancer: implications for use of lipids during nutrition support. Nutr Clin Pract. 2007;22(1): 74-88.
49. Meyers CD, Liu P, Kamanna VS, Kashyap ML. Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush. Atherosclerosis. 2007; 192(2):253-258.
50. Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem. 1957;226:497-509.
51. Xu Z, Harvey KA, Pavlina T, Dutot G, Zaloga GP, Siddiqui RA. An improved method for determining medium- and long-chain FAMEs using gas chromatography. Lipids. 2010;45:199-208.
52. Papaliodis D, Boucher W, Kempuraj D, et al. Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharmacol Exp Ther. 2008;327(3):665-672.
53. Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Prac. 2009;63(9): 1369-1377.
54. Christensen NA, Achor RW, Berge KG, Mason HL. Nicotinic acid treatment of hypercholesteremia. Comparison of plain and sustainedaction preparations and report of two cases of jaundice. JAMA. 1961;177:546-550.
55. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271(9):672-677.
56. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis. 2007;192(2):432-437.
57. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89(6):672-678.
58. Hunninghake DB, McGovern ME, Koren M, et al. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol. 2003;26(3): 112-118.
59. Bays HE, Ballantyne C. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol. 2009;20(6):467-476.
60. Cefali EA, Simmons PD, Stanek EJ, McGovern ME, Kissling CJ. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Ther. 2007;45(2):78-88.
61. Dunn RT, Ford MA, Rindone JP, Kwiecinski FA. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther. 1995;2(7):478-480.
62. Thakkar RB, Kashyap ML, Lewin AJ, Krause SL, Jiang P, Padley RJ. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs. 2009;9(2): 69-79.
63. Kaijser L, Eklund B, Olsson AG, Carlson LA. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol. 1979;57(2): 114-117.
64. Hirafuji M, Ebihara T, Kawahara F, Hamaue N, Endo T, Minami M. Inhibition by docosahexaenoic acid of receptor-mediated Ca(2+) influx in rat vascular smooth muscle cells stimulated with 5-hydroxytryptamine. Eur J Pharmacol. 2001;427(3):195-201.
65. Rinaldi B, Di Pierro P, Vitelli MR, et al. Effects of docosahexaenoic acid on calcium pathway in adult rat cardiomyocytes. Life Sci. 2002;71(9): 993-1004.
66. Hallaq H, Smith TW, Leaf A. Modulation of dihydropyridine-sensitive calcium channels in heart cells by fish oil fatty acids. Proc Natl Acad Sci U S A. 1992;89(5):1760-1764.
67. Xiao YF, Ke Q, Wang SY, et al. Single point mutations affect fatty acid block of human myocardial sodium channel alpha subunit Na+ channels. Proc Natl Acad Sci U S A. 2001;98(6):3606-3611.
68. Smith WL. Omega-3 and omega-6 essential fatty acids and cyclooxygenase pathways. Paper presented at: Experimental Biology; Apr 2006; San Fransico, CA.
69. Laneuville O, Breuer DK, Xu N, et al. Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)-octadecatrienoic acids from alphalinolenic acid. J Biol Chem. 1995;270(33):19330-19336.
70. Hwang D. Fatty acids and immune responses - a new perspective in searching for clues to mechanism. Annu Rev Nutr. 2000;20:431-456.
71. Corey EJ, Shih C, Cashman JR. Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci U S A. 1983;80(12):3581-3584.
72. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2011;142(5):687-698.
73. Siddiqui RA, Harvey KA, Zaloga GP. Modulation of enzymatic activities by n-3 polyunsaturated fatty acids to support cardiovascular health. J Nutr Biochem. 2008;19:417-443.